Merck KGaA Partners with Hengrui Pharma for Selective PARP1 Inhibitor and Antibody-Drug
By Ashish Tripathi
Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)
Published: 20 Nov-2023
DOI: 10.3833/pdr.v2023.i11.2837 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Merck KGaA has entered into an exclusive agreement with Jiangsu Hengrui Pharmaceuticals for ex-China rights to the latter’s HRS-1167 and SHR-A1904...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS